Anthracycline-free platinum-based neoadjuvant chemotherapy for triple-negative breast cancer: efficacy, safety, and clinicopathological predictors of response
Background: triple-negative breast cancer (TNBC) is associated with aggressive tumor biology and limited systemic treatment options. Incorporation of platinum agents into neoadjuvant chemotherapy (NACT) can increase pathological complete response (pCR) rates, but platinum-based regimens containing anthracyclines are of...